Silverarc Capital Management LLC Invests $7.92 Million in Scholar Rock Holding Co. (NASDAQ:SRRK)

Silverarc Capital Management LLC bought a new stake in shares of Scholar Rock Holding Co. (NASDAQ:SRRK - Free Report) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor bought 183,243 shares of the company's stock, valued at approximately $7,920,000. Scholar Rock accounts for approximately 1.7% of Silverarc Capital Management LLC's portfolio, making the stock its 19th biggest holding. Silverarc Capital Management LLC owned about 0.20% of Scholar Rock as of its most recent SEC filing.

Several other large investors also recently modified their holdings of SRRK. FMR LLC raised its stake in Scholar Rock by 33.7% in the fourth quarter. FMR LLC now owns 13,635,261 shares of the company's stock valued at $589,316,000 after purchasing an additional 3,439,215 shares in the last quarter. Vanguard Group Inc. raised its position in shares of Scholar Rock by 17.6% in the 4th quarter. Vanguard Group Inc. now owns 4,743,482 shares of the company's stock valued at $205,013,000 after buying an additional 708,817 shares in the last quarter. Marshall Wace LLP lifted its holdings in shares of Scholar Rock by 1,283.7% during the 4th quarter. Marshall Wace LLP now owns 2,945,408 shares of the company's stock worth $127,301,000 after acquiring an additional 2,732,546 shares during the period. Norges Bank acquired a new stake in shares of Scholar Rock during the 4th quarter worth approximately $86,043,000. Finally, Geode Capital Management LLC increased its stake in Scholar Rock by 14.7% in the fourth quarter. Geode Capital Management LLC now owns 1,770,324 shares of the company's stock valued at $76,530,000 after acquiring an additional 227,299 shares during the last quarter. 91.08% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Scholar Rock

In other news, insider Mo Qatanani sold 68,510 shares of the firm's stock in a transaction on Wednesday, February 19th. The shares were sold at an average price of $37.40, for a total transaction of $2,562,274.00. Following the completion of the transaction, the insider now owns 111,084 shares of the company's stock, valued at approximately $4,154,541.60. This trade represents a 38.15 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Tracey Sacco sold 6,500 shares of the business's stock in a transaction on Monday, March 24th. The stock was sold at an average price of $33.08, for a total transaction of $215,020.00. Following the completion of the sale, the insider now directly owns 71,750 shares in the company, valued at approximately $2,373,490. This represents a 8.31 % decrease in their position. The disclosure for this sale can be found here. Over the last three months, insiders sold 250,231 shares of company stock worth $9,056,086. 13.30% of the stock is currently owned by insiders.

Scholar Rock Price Performance

Shares of SRRK traded down $1.57 during trading hours on Friday, reaching $32.81. The stock had a trading volume of 694,304 shares, compared to its average volume of 1,240,686. The stock has a market capitalization of $3.11 billion, a PE ratio of -13.96 and a beta of 0.56. Scholar Rock Holding Co. has a 12 month low of $6.76 and a 12 month high of $46.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 3.88 and a current ratio of 3.88. The company's 50-day moving average is $32.77 and its two-hundred day moving average is $35.60.

Wall Street Analysts Forecast Growth

Separately, Wedbush reaffirmed an "outperform" rating and issued a $50.00 target price on shares of Scholar Rock in a report on Tuesday, March 25th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat.com, Scholar Rock has a consensus rating of "Buy" and a consensus target price of $42.67.

Scholar Rock Profile

Scholar Rock Holding Corporation, a biopharmaceutical company, focuses on the discovery, development, and delivery of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, an inhibitor of the activation of myostatin that is in Phase 3 clinical trial for the treatment of spinal muscular atrophy; and SRK-181, which has completed Phase 1 clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody therapies.